Global Longlife Hospital and ResearchShare price, financial results, shareholding and management
- Market cap
- ₹15 cr
- Stock P/E
- 75.9peers 72.8
- Book value
- ₹25.5
- Price to book
- 0.57
- EV / operating profit
- -
- Market cap to sales
- 26.21
- ROCE · FY25
- 1.2%
- ROE · FY25
- 0.8%
- ROE, 3-year average
- 0.1%
- Operating margin · FY25
- -720.8%peers 13.4%
- Sales growth, 3 years
- -73.9%
- Profit growth, 3 years
- -61.7%
- Debt to equity
- 0.00peers 0.11
- Borrowings
- ₹0 cr
- Interest cover
- 1.4×
- Cash from business / op. profit
- -296%
- Debtor days
- 377
- Pledged
- 0.00%
- Promoter holding
- 22.88%
- Change in promoter holding
- 0.00 pts
- Shareholders
- 1,133
- 52-week high / low
- ₹26 / ₹9
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
Global Longlife Hospital and Research share price chart
Close on 6 Nov 2026 · +3.36% on the day · Vol 1.06 L
Daily prices to 6 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 6 Nov 2026
- 1 month
- +18.2%
- 3 months
- +10.8%
- 6 months
- +8.2%
- 1 year
- -39.1%
- Traded a day, 20 days
- ₹0.12 cr
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY25 on FY24 | -96% | - |
| 3 years, a year | -74% | -62% |
| Latest half, H1 FY25 | -95% | +20% |
About Global Longlife Hospital and Research: business, products and customers
Global Longlife Hospital and Research ran a multi speciality hospital in Ahmedabad, but it no longer earns money from patients and now plans to change its name and move into trading farm produce, textiles and metals. Its shares trade on BSE SME.
At its 2022 listing the company ran Global Hospital at Bodakdev, Ahmedabad, a hospital it owned, with medical and surgical specialities, an accreditation from NABH and an open model in which any doctor with more than three years of experience could admit patients there. Revenue came from patients' bills, and most doctors worked as visiting consultants rather than employees.
That business has wound down. Revenue from operations fell to almost nothing in FY25 and to nil in FY26; the registered office moved out of the hospital building to an office in Ahmedabad in October 2024; and the company had three permanent employees at March 2026. The readable pages of the annual reports do not say what became of the hospital itself.
Read more about the business
In FY25 the company still reported a small profit only because of a large one-time other income, and in FY26, with no revenue, it reported a loss. The board now proposes a new name (Kanzi, Asahi or Siddhaa Enterprise) and new objects covering trading of food grains, oilseeds, cotton, textiles and gold and silver, saying it plans a new line of business.
The offer document said it competed with large corporate hospitals, single speciality hospitals and clinics in Ahmedabad; it named no listed peers. Listed SME hospitals in Gujarat such as Aashka Hospitals, KK Shah Hospitals and Broach Lifecare Hospital run the kind of business it used to run.
From the offer document (Prospectus, April 2022), the FY25 and FY26 annual reports and the Regulation 29 disclosure of 25 September 2026.
Read the deeper study ↓In its favour
- It brings in more cash than it shows as profit: ₹12.3 cr against ₹0.2 cr in FY25.
- It has little debt for its size: debt to equity 0.00.
To watch
- Approval of the new name and objects, and what the extraordinary general meeting noticed on 7 October 2026 is for (Annual report FY26, p.6 to 7; Announcement, 7 October 2026, subject line only).
- The first revenue from the planned trading business (Annual report FY26, p.16).
- Use of the money held in current assets at March 2026 (Annual report FY26, p.53).
- Further changes in large holdings after the Kamdar HUF purchase of September 2026 (Regulation 29(1) disclosure, 25 September 2026).
- Customers take longer to pay than before: 377 days in FY25, against 95 in FY19.
From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.
Global Longlife Hospital and Research revenue and profit growth
Half-yearly results · Profit and lossSales have fallen.
SME companies report every six months. In the latest half, sales were lower than in the same half a year before. Profit grew faster than sales.
Global Longlife Hospital and Research half-yearly results
SME companies report every six months · ₹ crore
| H1FY22 | H2FY22 | H1FY23 | H2FY23 | H1FY24 | H2FY24 | H1FY25 | |
|---|---|---|---|---|---|---|---|
| Sales | 19.94 | 12.87 | 11.80 | 11.70 | 12.33 | 1.19 | 0.58 |
| Expenses | 13.18 | 11.61 | 10.02 | 9.44 | 9.62 | 4.20 | 4.39 |
| Operating profit | 6.76 | 1.26 | 1.78 | 2.26 | 2.71 | -3.02 | -3.82 |
| OPM | 33.9% | 9.8% | 15.1% | 19.3% | 22.0% | -254.7% | -661.6% |
| Interest | 0.09 | 1.31 | 0.20 | 0.20 | 0.41 | 0.36 | 0.28 |
| Depreciation | 0.58 | 0.57 | 0.58 | 0.59 | 0.61 | 0.64 | 0.48 |
| Profit before tax | 6.16 | -0.46 | 1.06 | 1.64 | 1.71 | -3.98 | 1.11 |
| Net profit | 6.17 | -0.10 | 0.76 | 1.07 | 1.03 | -3.22 | 1.24 |
Global Longlife Hospital and Research profit and loss
Full years to March, FY19 to FY25 · ₹ crore, consolidated where reported
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|---|---|
| Sales | 33.44 | 33.32 | 32.70 | 32.44 | 23.50 | 13.52 | 0.58 |
| Expenses | 26.61 | 29.88 | 27.26 | 24.14 | 19.47 | 13.83 | 4.74 |
| Operating profit | 6.83 | 3.44 | 5.44 | 8.30 | 4.04 | -0.31 | -4.16 |
| OPM | 20.4% | 10.3% | 16.6% | 25.6% | 17.2% | -2.3% | -720.8% |
| Other income | 0.08 | 0.03 | 0.06 | 0.17 | 0.24 | 0.06 | 5.02 |
| Interest | 2.07 | 2.41 | 2.44 | 1.62 | 0.40 | 0.77 | 0.28 |
| Depreciation | 2.15 | 2.13 | 1.31 | 1.14 | 1.17 | 1.25 | 0.48 |
| Profit before tax | 2.69 | -1.07 | 1.75 | 5.71 | 2.71 | -2.27 | 0.10 |
| Tax rate | 49.4% | -18.7% | -17.1% | 37.5% | 32.5% | 3.4% | -101.0% |
| Net profit | 1.36 | -0.86 | 2.05 | 3.57 | 1.83 | -2.19 | 0.20 |
| EPS ₹ | 1.94 | -1.23 | 2.93 | 5.10 | 1.79 | -2.08 | 0.19 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
A tax rate above 60% or below zero (FY20, FY21, FY25) comes from tax charged on a small or negative profit, as reported.
Earnings per share before FY25 is on the share count of that time, before later bonus or share issues, so it does not compare with the years after.
Global Longlife Hospital and Research profitability
Margins and returns on capitalLast year the company kept less from each rupee of sales than the year before. Its costs were more than its sales. It earns a low return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|---|---|
| Operating margin | 20.4% | 10.3% | 16.6% | 25.6% | 17.2% | -2.3% | -720.8% |
| Tax rate | 49.4% | -18.7% | -17.1% | 37.5% | 32.5% | 3.4% | -101.0% |
| ROCE | · | 3.6% | 12.8% | 26.0% | 6.3% | -2.7% | 1.2% |
| ROE | · | -7.2% | 16.3% | 23.3% | 4.5% | -4.9% | 0.8% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Global Longlife Hospital and Research debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown. It has almost no borrowings. Last year the business brought in more cash than it showed as profit. Customers take longer to pay than they did in FY23, which ties up more of the company's money in unpaid bills.
Bars below the line are cash going out.
Global Longlife Hospital and Research balance sheet
At each 31 March · ₹ crore
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|---|---|
| Equity capital | 7 | 7 | 7 | 7 | 10.50 | 10.50 | 10.50 |
| Reserves | 5.35 | 4.49 | 6.68 | 9.96 | 53.79 | 15.43 | 16.29 |
| Net worth | 12.35 | 11.49 | 13.68 | 16.96 | 64.29 | 25.93 | 26.79 |
| Borrowings | 27.18 | 23.51 | 17.04 | 8.69 | 9.29 | 12.74 | 0 |
| Other liabilities | 3.77 | 6.92 | 6.06 | 8.33 | 2.36 | 3.07 | 0.06 |
| Total liabilities | 43.30 | 41.92 | 36.78 | 33.98 | 75.94 | 41.74 | 26.85 |
| Fixed assets | 20.17 | 18.72 | 17.46 | 16.71 | 16.52 | 17.27 | 0 |
| Capital work in progress | 0 | 0 | 0 | 0 | 1.03 | 0 | 0 |
| Investments | 0.10 | 0.10 | 0.47 | 0.10 | 0.10 | 0.03 | 0.03 |
| Other assets | 23.03 | 23.10 | 18.85 | 17.17 | 58.29 | 24.44 | 26.82 |
Global Longlife Hospital and Research cash flow
₹ crore
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|---|---|
| Cash from operations | 5.40 | 3.90 | 6.88 | 9.42 | -40.42 | -5.07 | 12.32 |
| Cash from investing | -0.33 | -0.04 | 0.02 | 0.01 | -1.90 | -0.82 | 21.80 |
| Cash from financing | -4.77 | -3.05 | -7.22 | -9.66 | 45.70 | 2.67 | -13.01 |
| Net cash flow | 0.30 | 0.81 | -0.32 | -0.23 | 3.38 | -3.22 | 21.11 |
Working capital
Days
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 95 | 69 | 88 | 100 | 151 | 53 | 377 |
| Inventory days | 169 | 158 | 34 | 89 | 69 | 132 | 0 |
| Days payable | 230 | 392 | 139 | 433 | 110 | 766 | · |
| Cash conversion cycle | 34 | -165 | -17 | -244 | 110 | -581 | 377 |
| Working capital days | 19 | 12 | 7 | -30 | 345 | -238 | 1,283 |
Global Longlife Hospital and Research peers and competitors
Listed SME companies in the same industryBy sales, Global Longlife Hospital and Research is number 23 of the 23 listed SME companies in healthcare services.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Maitreya Medicare | 79 | - | 44.9 | -2.5 | -0.7% | 0.80 |
| Invicta Diagnostic | 81 | 16.6 | 32.4 | 4.9 | 30.2% | 0.07 |
| Nidan Laboratories and Healthcare | 18 | 12.2 | 25.5 | 1.5 | 19.0% | 0.16 |
| Aatmaj Healthcare | 52 | 72.7 | 24.3 | 0.7 | 9.7% | 0.41 |
| Aashka Hospitals | 244 | 73.0 | 23 | 3.3 | 22.8% | 0.08 |
| Clinitech Laboratory | 7 | 17.4 | 9.5 | 0.4 | 10.4% | 0.06 |
| KK Shah Hospitals | 31 | - | 9.3 | -0.6 | 8.3% | 0.00 |
| Broach Lifecare Hospital | 8 | 94.4 | 6 | 0.1 | 8.5% | 0.00 |
| Dr Lalchandani Labs | 6 | 93.3 | 4.2 | 0.1 | 16.5% | 0.15 |
| Vanta Bioscience | 15 | 132.0 | 1.8 | 0.1 | 56.0% | 1.80 |
| Global Longlife Hospital and Research | 15 | 75.9 | 0.6 | 0.2 | -720.8% | 0.00 |
| Median of the 10 others | 25 | 72.9 | 16.3 | 0.3 | 13.4% | 0.11 |
Global Longlife Hospital and Research shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own less than half the company, a little less than in the first filing shown. Big foreign and Indian funds own very little. The number of shareholders is about the same.
Global Longlife Hospital and Research shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | |
|---|---|---|---|---|---|---|---|---|
| Promoters | 54.29% | 54.29% | 54.29% | 54.90% | 55.10% | 35.44% | 22.88% | 22.88% |
| Number of shareholders | 974 | 989 | 938 | 917 | 915 | 985 | 1,149 | 1,133 |
Global Longlife Hospital and Research study: the business from its own documents
Read from 3 of the company's own documentsGlobal Longlife Hospital and Research key facts from the filings
Each figure with the document it comes from
- FY26 revenue
- Nil
- No revenue from operations, against ₹0.58 cr in FY25 and ₹13.5 cr in FY24.Annual report FY26, p.29; Annual report FY25, p.16
- FY26 loss
- ₹1.7 cr
- Loss after tax, including ₹0.73 cr for earlier years' tax; FY25 showed a profit of ₹0.20 cr.Annual report FY26, p.29
- FY25 other income
- ₹5.0 cr
- Other income in the year the hospital revenue fell away, against ₹0.06 cr a year earlier; the readable pages do not say what it was.Annual report FY25, p.16
- Hospital at listing
- 110 beds
- Owned hospital at Bodakdev with 11 full time consultants, over 30 visiting doctors and 37 nurses in December 2021.Offer document, p.17 and p.85
- Employees
- 3
- Permanent employees at March 2026, against 90 hospital staff besides doctors in December 2021.Annual report FY26, p.43; Offer document, p.84 to 85
Show 5 more facts
- Office moved
- October 2024
- The registered office left the hospital building for an office on Sindhu Bhavan Road, Ahmedabad.Annual report FY25, p.17
- New name proposed
- Three options
- Kanzi, Asahi or Siddhaa Enterprise, with new objects in food grains, oilseeds, cotton, textiles and bullion; approved by the board in May 2026.Annual report FY26, p.6 to 7 and p.12
- Net worth
- ₹23.7 cr
- At March 2026, held almost entirely in current assets; the current ratio was over a thousand times.Annual report FY26, p.15 and p.53
- Promoter holding
- 22.88%
- In the June 2026 shareholding pattern; Dhruv Jani held 24,00,990 shares.Shareholding pattern, June 2026; Annual report FY26, p.28
- New 5% holder
- 5.09%
- Abhishek Ashvinbhai Kamdar HUF, not in the promoter group, crossed five per cent through open market purchases on 25 September 2026.Regulation 29(1) disclosure, 25 September 2026, p.2 to 3
What the company said, and what happened
The company's own statements, attributed, set against what it later reported; not newboard's estimates
The company says it plans to change its name and objects and take up a new line of business, and its FY26 management discussion lists expanding into markets and a stronger supply chain as aims for FY27. No order, customer, cost or date for the new business is given. Members were asked to approve the new name, the new objects and the Managing Director's reappointment, with basic pay of up to ₹36 lakh a year, at the 2026 annual general meeting. The company filed a change of name on 28 September 2026 and a notice of an extraordinary general meeting on 7 October 2026 (only their subject lines were available here).
Is it a good business? Six questions
Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.
The company listed as a hospital but no longer earns anything from patients, and it now plans to become a trading company in farm goods, textiles and metals.
What remains is a balance sheet of mostly current assets, a tiny staff and a new business that has not started.
WatchCan it set its own prices?With no revenue there are no prices to set, and the planned trading in commodities is a business where market prices rule.
WatchHow strong is it against rivals?Even as a running hospital it faced larger chains, and it now has no operating business to defend.
WatchWho are its customers?Patients were its customers; today it has none, and the filings name no customers for the new trading plans.
AverageDoes it need a lot of money?It has no borrowings to service and most of its net worth sits in current assets, so the question is how that money will be used.
WatchCan it keep finding new work?No new work is in hand; the company has only stated that it plans a new line of business.
WatchDo good and bad years swing a lot?Results have swung from steady hospital revenue to nothing, and one year's profit rested on one-time income.
Who runs Global Longlife Hospital and Research?
Promoters, directors and officers; tap a name for the background
DJDhruv JaniPromoter and Managing Director · holds 22.87%
Holds a Bachelor of Business Administration from Gujarat University and has more than ten years in the cotton and oil business. With the company since 2015 and Managing Director since September 2021, in charge of finance, overall management and operations; proposed for reappointment for five years from September 2026. Drew ₹12 lakh in FY26.
Annual report FY26, p.13 and p.42; Offer document, p.102SJSucheta JaniNon-Executive Director
Holds a Bachelor of Engineering in Information Technology from Gujarat Technological University; on the board since September 2021, advising on expansion and the company's IT. The annual report states that Sucheta Jani is the wife of Dhruv Jani.
Annual report FY26, p.14 and p.28; Offer document, p.102HTHetal ThakkarExecutive Director and Chief Financial Officer
Holds a BBA and an MBA, with ten years of experience; joined in March 2016, earlier worked at Nutec Infotech, and became an Executive Director in August 2024.
Annual report FY26, p.43; Annual report FY25, p.17SJSureshkumar JaniPromoter, former Chairman
Named a promoter in the offer document, which describes an MBA from Allahabad University and more than thirty years in cotton, oil and construction. Resigned as Chairman and Director in October 2024.
Offer document, p.17 and p.102; Annual report FY25, p.17MTManasvi ThaparIndependent Director
Holds a BA LLB (Hons.) from Nirma University and runs a legal practice, Candour Legal; on the board since August 2021 and also a director of City Pulse Multiventures.
Annual report FY26, p.28; Offer document, p.102HMHiren MandaliyaIndependent Director
A Chartered Accountant with expertise in accounting and taxation; appointed in March 2026.
Annual report FY26, p.28 and p.30Global Longlife Hospital and Research latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H1 FY25: sales ₹0.6 cr (-95%), net profit ₹1.2 cr (+20%) on H1 FY24.
- Shareholding, 30 June 2026: promoters unchanged at 22.88%.
Global Longlife Hospital and Research announcements
6 on record, latest first; each opens the filing on the exchange
- Company UpdatePublication of Newspaper Advertisement of Notice of First Extra Ordinary General Meeting and E Voting InformationPDF ↗
- AGM/EGMNotice of EGMPDF ↗
- OthersOutcome of the Meeting of Board of DirectorsPDF ↗
- Insider Trading / SASTIntimation of Closure of Trading WindowPDF ↗
- Company UpdateChange in name of the companyPDF ↗
- Insider Trading / SASTThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Abhishek AshvinbhaPDF ↗
Global Longlife Hospital and Research annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
Global Longlife Hospital and Research share split, bonus and dividends
From the corporate actions the company announces on the exchange
No share split, bonus issue or dividend is on record since listing.
Checks we ran on Global Longlife Hospital and Research's data · 7
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- ✓Balance sheet totals add up for FY24 and FY25.
- ✓Market cap uses the share count in the latest shareholding pattern (1,05,00,000 shares).
- ✓The share capital in the FY25 results matches the share count in the shareholding pattern.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓Earnings per share moves in line with profit across the years shown.
- ✓Revenue and profit are reported for every year shown, FY19 to FY25.
- iPrices run to the close on 12 Oct 2026, from the exchange's daily figures.
Questions people ask about Global Longlife Hospital and Research
What does Global Longlife Hospital and Research do?
Global Longlife Hospital and Research ran a multi speciality hospital in Ahmedabad, but it no longer earns money from patients and now plans to change its name and move into trading farm produce, textiles and metals. Its shares trade on BSE SME.
What is the share price of Global Longlife Hospital and Research?
₹14.5 at the close on 6 Nov 2026, from the exchange's daily figures.
What is the market cap of Global Longlife Hospital and Research?
₹15 cr at the close on 6 Nov 2026, on 1,05,00,000 shares.
What is the P/E of Global Longlife Hospital and Research?
75.9 times FY25 profit at the close on 6 Nov 2026 (our arithmetic).
What are Global Longlife Hospital and Research's revenue and profit?
Revenue ₹1 cr and profit after tax ₹0 cr in FY25.
Who are the promoters of Global Longlife Hospital and Research?
Dhruv Jani, Sureshkumar Jani; promoters held 22.88% at 30 June 2026.
What is Global Longlife Hospital and Research's website?
www.globalhospital.co.in
More SME companies like Global Longlife Hospital and Research
Other listed SME companies in healthcare services, the closest in size first, each read from its own documents.
- Vanta BioscienceVANTABIO · BSE SME · Healthcare ServicesMarket cap ₹16 cr
- Nidan Laboratories and HealthcareNIDAN · NSE Emerge · Healthcare Services · listed 2021Market cap ₹17 cr
- Broach Lifecare HospitalBROACH · BSE SME · Healthcare ServicesMarket cap ₹8 cr
- KK Shah HospitalsKKSHL · BSE SME · Healthcare ServicesMarket cap ₹31 cr
- Clinitech LaboratoryCTLLAB · BSE SME · Healthcare ServicesMarket cap ₹7 cr
- Dr Lalchandani LabsDLCL · BSE SME · Healthcare ServicesMarket cap ₹6 cr
Built from 2 annual reports, 1 offer document, 6 exchange announcements, 8 shareholding patterns and 7 years of reported results. Every figure carries its source; where the documents are silent, the page says so.